...
首页> 外文期刊>Circulation journal >ABO Blood Type and Response of Activated Partial Thromboplastin Time to Dabigatran in Nonvalvular Atrial Fibrillation Patients
【24h】

ABO Blood Type and Response of Activated Partial Thromboplastin Time to Dabigatran in Nonvalvular Atrial Fibrillation Patients

机译:非瓣膜性房颤患者的ABO血型和活化的部分凝血活酶时间对达比加群的响应

获取原文
           

摘要

Background: The association between ABO blood type and the activated partial thromboplastin time (aPTT) under dabigatran therapy in nonvalvular atrial fibrillation (NVAF) patients is unclear. Methods?and?Results: Between 2011 March and 2015 May, data on ABO blood type and aPTT under dabigatran were obtained for 396 NVAF patients (baseline aPTT, 166). The prevalence of blood type O tended to increase or significantly increase according to baseline aPTT, aPTT under dabigatran, and their difference (?aPTT) (P=0.054, 0.001, and 0.012, respectively). Conclusions: In these NVAF patients, a high aPTT value under dabigatran therapy was associated with blood type O. ( Circ J 2015; 79: 2274–2277)
机译:背景:达比加群治疗下非瓣膜性心房颤动(NVAF)患者的ABO血型与活化的部分凝血活酶时间(aPTT)之间的关系尚不清楚。方法和结果:在2011年3月至2015年5月之间,获得了396例NVAF患者的达比加群ABO血型和aPTT数据(基线aPTT,166)。根据基线aPTT,达比加群(dabigatran)下的aPTT及其差异(ΔaPTT)(分别为P = 0.054、0.001和0.012),O型血型流行趋势倾向于增加或显着增加。结论:在这些NVAF患者中,达比加群治疗下的aPTT值高与O型血有关(Circ J 2015; 79:2274–2277)

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号